Citations

Clear

3314 citation(s) found for "Yu, Alexander".

The current state of digital pathology, molecular diagnostics and biobanking in renal cancer: Kidney Cancer Association Consensus Statement
Leibovich, Bradley C. , George, Daniel J. , Pickering, Lisa , Blackmur, James Peter , Jones, James O. , Laird, Alexander , Warren, Anne Y. , George, Daniel J. , Rosa, Salvatore La , Stewart, Grant D.

Mayo Clinic

Medicom Conference Report Proceedings of the 2024 IKCS: Europe Symposium | October 17, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.55788/bba1f0bd Get It

A Transfer Learning-Based Framework for Classifying Lymph Node Metastasis in Prostate Cancer Patients
Sarkar, S. , Harwood, Matthew , Silva, Alvin C. , Sarkar, Suryadipto , Harwood, Matthew , Wu, Teresa

Mayo Clinic

Biomedicines | October 15, 2024 | Volume: 12 | Issue: 10 | Pages: 2345

10.3390/biomedicines12102345 | PMID 39457657 Get It

Background: Prostate cancer is the second most common new cancer diagnosis in the United States. It is usually slow-growing, and when it is low-grade and confined to the prostate gland, it can be treated either conservatively (through active surveillance) or with surgery. However, if the cancer has spread beyond the prostate, such as to the lymph nodes, then that indicates a more aggressive cancer, and surgery may not be adequate. Methods: The challenge is that it is often difficult for radiologists reading prostate-specific imaging such as magnetic resonance images (MRIs) to differentiate malignant lymph nodes from non-malignant ones. An emerging field is the development of artificial intelligence (AI) models, including machine learning and deep learning, for medical imaging to assist in diagnostic tasks. Earlier research focused on implementing texture algorithms to extract imaging features used in classification models. More recently, researchers began studying the use of deep learning for both stand-alone feature extraction and end-to-end classification tasks. In order to tackle the challenges inherent in small datasets, this study was designed as a scalable hybrid framework utilizing pre-trained ResNet-18, a deep learning model, to extract features that were subsequently fed into a machine learning classifier to automatically identify malignant lymph nodes in patients with prostate cancer. For comparison, two texture algorithms were implemented, namely the gray-level co-occurrence matrix (GLCM) and Gabor. Results: Using an institutional prostate lymph node dataset (42 positives, 84 negatives), the proposed framework achieved an accuracy of 76.19%, a sensitivity of 79.76%, and a specificity of 69.05%. Using GLCM features, the classification achieved an accuracy of 61.90%, a sensitivity of 74.07%, and a specificity of 42.86%. Using Gabor features, the classification achieved an accuracy of 65.08%, a sensitivity of 73.47%, and a specificity of 52.50%. Conclusions: Our results demonstrate that a hybrid approach, i.e., using a pre-trainined deep learning model for feature extraction, followed by a machine learning classifier, is a viable solution. This hybrid approach is especially useful in medical-imaging-based applications with small datasets.
DICER1 -Related Tumor Predisposition: Identification of At-risk Individuals and Recommended Surveillance Strategies
Schultz, Kris Ann P. , Nelson, Alexander T. , Mallinger, Paige, Harris, Anne K. , Kamihara, Junne , Baldinger, Shari , Chen, Kenneth , Pond, Dinel , Hatton, Jessica N. , Dybvik, Anna, Perrino, Melissa R. , Ami, Tal Ben , Su, Yan , Duan, Cuihai , Watson, David , Field, Amanda L., Carr, Ann G. , Schneider, Dominik T. , Schoettler, Peter , Dehner, Louis P. , Mallinger, Paige H R , Chen, Kenneth S , Dybvik, Anna G , Mitchell, Sarah G , Perrino, Melissa R , Ben-Ami, Tal , Kachanov, Denis , Su, Yan , Duan, Chao , Olson, Damon R , Watson, Dave , Field, Amanda L , Harney, Laura A , Garrity Carr, Ann , Frazier, A Lindsay , Schneider, Dominik T , Wilson, David B , MacFarland, Suzanne P , Schoettler, Peter J , Bauer, Andrew J , Dehner, Louis P , Hill, Dana Ashley , Stewart, Douglas R , Messinger, Yoav H , Harris, Anne K , Olson, Damon R. , Wilson, David B. , Messinger, Yoav H.

Mayo Clinic

Clinical Cancer Research | October 14, 2024 | Volume: 30 | Issue: 24 | Pages: 5681-5692

10.1158/1078-0432.ccr-24-1532 | PMID 39400264 Get It

Abstract Purpose: DICER1-related tumor predisposition increases risk for a spectrum of benign and malignant tumors. In 2018, the International Pleuropulmonary Blastoma (PPB)/DICER1 Registry published guidelines for testing- and imaging-based surveillance of individuals with a known or suspected germline DICER1 pathogenic or likely pathogenic (P/LP) variant. One of the goals of the Registry is to continue to refine these guidelines as additional data become available. Experimental Design: Individuals were enrolled in the International PPB/DICER1 Registry, the International Ovarian and Testicular Stromal Tumor Registry, and/or the NCI Natural History of DICER1 Syndrome study. Results: Review of participant records identified 713 participants with a germline DICER1 P/LP variant from 38 countries. To date, 5 cases of type I and 29 cases of type Ir PPB have been diagnosed by surveillance in enrolled individuals. One hundred and three individuals with a germline P/LP variant developed a primary ovarian Sertoli–Leydig cell tumor at a median age of 14 years (range: 11 months–66 years); 13% were diagnosed before 8 years of age, the current age of onset of pelvic surveillance. Additionally, 4% of Sertoli–Leydig cell tumors were diagnosed before 4 years of age. Conclusions: Ongoing data collection highlights the role of lung surveillance in the early detection of PPB and suggests that imaging-based detection and early resection may decrease the risk of advanced PPB. DICER1-related ovarian tumors were detected before 8 years of age, prompting the Registry to recommend earlier initiation of ovarian surveillance with pelvic ultrasound beginning at the time of detection of a germline DICER1 P/LP variant.
Cardiac troponin elevation and mortality in takotsubo syndrome: New insights from the international takotsubo registry
Stähli, Barbara E. , Schindler, Matthias , Schweiger, Victor , Cammann, Victoria L. , Szawan, Konrad A. , Niederseer, David , Würdinger, Michael , Schönberger, Alexander, Schönberger, Maximilian, Koleva, Iva, Mercier, Julien C., Petkova, Vanya, Mayer, Silvia, Gili, Sebastiano , Franke, Jennifer , Meder, Benjamin , Jaguszewski, Miłosz, Knorr, Maike, Jansen, Thomas , Lewinski, Dirk von , Burgdorf, Christof , Kherad, Behrouz , Tschöpe, Carsten , Sarcon, Annahita, Shinbane, Jerold S., Rajan, Lawrence, Michels, Guido, Pfister, Roman , Jacobshagen, Claudius, Karakas, Mahir , Pott, Alexander , Meyer, Philippe , Roffi, Marco , Wolfrum, Mathias , Fischer, Thomas, Vasankari, Tuija , Dworakowski, Rafał , MacCarthy, Philip , Osswald, Stefan , Galiuto, Leonarda , Chan, Christina , Bridgman, Paul , Beug, Daniel , Gilyarova, Ekaterina, Gilyarov, Mikhail , Akın, İbrahim , Poledníková, Karolína, Massoomi, Michael , Carrilho‐Ferreira, Pedro , Hauck, Christian , Paolini, Carla , Bilato, Claudio , Kobayashi, Yoshio , Ishibashi, Iwao, Himi, Toshiharu, Din, Jehangir , Rihal, Charanjit S. , Liu, Kan , Jörg, Lucas, Rickli, Hans , Böhm, M., Pinto, Fausto J. , Widimský, Petr , Felix, Stephan B. , Rottbauer, Wolfgang , Budnik, Monika , Opolski, Grzegorz , Thiele, Holger, Kong, William, Dalakoti, Mayank , Imori, Yoichi , Liberale, Luca , Münzel, Thomas , Bax, J. J., Ghadri, Jelena R. , Vece, Davide Di , Templin, Christian , Budnik, Monika , Roffi, Marco , Liberale, Luca , Montecucco, Fabrizio , von Lewinski, Dirk , Tschöpe, Carsten , Meyer, Philippe , Bilato, Claudio , Citro, Rodolfo , Vecchione, Carmine , Bossone, Eduardo , Neuhaus, Michael, Noutsias, Michel , D’Ascenzo, Fabrizio, Dichtl, Wolfgang , Cuneo, Alessandro , Köenig, Wolfgang , Banning, Adrian , Cuculi, Florim , Kobza, Richard , Airaksinen, Juhani , Napp, L. Christian , Kaiser, Christoph A. , Delmas, Clément , Lairez, Olivier , Shilova, Alexandra S. , El‐Battrawy, Ibrahim , Toušek, Petr , Winchester, David E. , Gałuszka, Jan , Ukena, Christian , Poglajen, Gregor , Kato, Ken , Al‐Shammari, Ali Saad , Prasad, Abhiram , Rihal, Charanjit S. , Schulze, Paul Christian , Bianco, Matteo , Pestana, Gonçalo , Nguyen, Thanh Ha Tuan , Maier, Lars S. , Braun-Dullaeus, Ruediger Christian , Hasenfuß, Gerd , Pieske, Burkert , Schunkert, Heribert , Thiele, Holger , Bauersachs, Johann , Horowitz, John D. , Mario, Carlo Di , Crea, Filippo , Luescher, T F , Ruschitzka, Frank T.

Mayo Clinic

European Journal of Clinical Investigation | October 14, 2024 | Volume: 54 | Issue: 12 | Pages: No page available

10.1111/eci.14317 | PMID 39397275 Get It

AbstractBackgroundThe clinical relevance of cardiac troponin (cTn) elevation in takotsubo syndrome (TTS) remains uncertain. The present study sought to investigate the role of cardiac troponin (cTn) elevations in mortality prediction of patients with Takotsubo syndrome (TTS).MethodsPatients enrolled in the International Takotsubo (InterTAK) Registry from January 2011 to February 2020 with available data on peak cTn levels were included in the analysis. Peak cTn levels during the index hospitalization were used to define clinically relevant myocardial injury. The threshold at which clinically relevant myocardial injury drives mortality at 1 year was identified using restricted cubic spline analysis.ResultsOut of 2′938 patients, 222 (7.6%) patients died during 1‐year follow‐up. A more than 28.8‐fold increase of cTn above the upper reference limit was identified as threshold for clinically relevant myocardial injury. The presence of clinically relevant myocardial injury was significantly associated with an increased risk of mortality at 5 years (adjusted HR 1.58, 95% CI 1.18–2.12, p =.002). Clinically relevant myocardial injury was related to an increased 5‐year mortality risk in patients with apical TTS (adjusted HR 1.57, 95% CI 1.21–2.03, p =.001), in presence of physical stressors (adjusted HR 1.60, 95% CI 1.22–2.11, p =.001), and in absence of emotional stressors (adjusted HR 1.49, 95% CI, 1.17–1.89, p =.001).ConclusionThis study for the first time determined a troponin threshold for the identification of TTS patients at excess risk of mortality. These findings advance risk stratification in TTS and assist in identifying patients in need for close monitoring and follow‐up.
Multidisciplinary management strategies for recurrent brain metastasis after prior radiotherapy: An overview
Kotecha, Rupesh , Rosa, Alonso La , Brown, Paul D. , Vogelbaum, Michael A. , Navarria, Pierina , Bodensohn, Raphael , Karschnia, Philipp , La Rosa, Alonso , Karschnia, Philipp , Niyazi, Maximilian , Minniti, Giuseppe

Mayo Clinic

Neuro-Oncology | October 11, 2024 | Volume: 27 | Issue: 3 | Pages: 597-615

10.1093/neuonc/noae220 | PMID 39495010 Get It

Abstract As cancer patients with intracranial metastatic disease experience increasingly prolonged survival, the diagnosis and management of recurrent brain metastasis pose significant challenges in clinical practice. Prior to deciding upon a management strategy, it is necessary to ascertain whether patients have recurrent/progressive disease vs adverse radiation effect, classify the recurrence as local or distant in the brain, evaluate the extent of intracranial disease (size, number and location of lesions, and brain metastasis velocity), the status of extracranial disease, and enumerate the interval from the last intracranially directed intervention to disease recurrence. A spectrum of salvage local treatment options includes surgery (resection and laser interstitial thermal therapy [LITT]) with or without adjuvant radiotherapy in the forms of external beam radiotherapy, intraoperative radiotherapy, or brachytherapy. Nonoperative salvage local treatments also range from single fraction and fractionated stereotactic radiosurgery (SRS/FSRS) to whole brain radiation therapy (WBRT). Optimal integration of systemic therapies, preferably with central nervous system (CNS) activity, may also require reinterrogation of brain metastasis tissue to identify actionable molecular alterations specific to intracranial progressive disease. Ultimately, the selection of the appropriate management approach necessitates a sophisticated understanding of patient, tumor, and prior treatment-related factors and is often multimodal; hence, interdisciplinary evaluation for such patients is indispensable.
Vasculitis associated with VEXAS syndrome
Sullivan, Megan M. , Mead‐Harvey, Carolyn , Sartori‐Valinotti, Julio C. , Kalantari, Kambiz , Kusne, Yael , Patnaik, Mrinal M. , Mangaonkar, Abhishek A. , Montes, Daniel , Reichard, Kaaren K. , Olteanu, Horatiu , Bois, Melanie C. , Hines, Alexander , Olteanu, Horatiu , Hines, Alexander S , Warrington, Kenneth J , Sullivan, Megan M , Go, Ronald S. , Warrington, Kenneth J. , Koster, Matthew J.

Mayo Clinic

Rheumatology | October 11, 2024 | Volume: 64 | Issue: 6 | Pages: 3889-3894

10.1093/rheumatology/keae550 | PMID 39392442 Get It

Abstract Objectives To define the prevalence, distribution and characteristics of patients with VEXAS (vacuoles, E1-enzyme, X-linked, autoinflammation, somatic) syndrome who have confirmed vasculitis. Methods Patients with VEXAS syndrome, verified by positive UBA1 mutation, were included. Chart review was performed to identify patient characteristics and outcomes. Vasculitis diagnosis was based on either histopathology showing vascular inflammation or non-invasive angiography findings. Summary statistics were calculated. Results Eighty-nine patients met inclusion criteria. All were male with a median age of onset of 66.9 years (interquartile range 60.1, 72.7). Median (interquartile range) follow-up was 3.8 (2.2–5.5) years, during which 21 patients (23.6%) had evidence of vasculitis. Vasculitis subtypes included small vessel vasculitis (19.1%), cutaneous medium vessel vasculitis (2.2%) and large vessel vasculitis (2.2%). No patient had more than one vessel size involved. Histopathology in small vessel vasculitis patients was consistent with cutaneous leukocytoclastic vasculitis in the majority, though one patient had leukocytoclastic peritubular capillaritis on renal biopsy. Cranial symptoms (headache, vision changes or jaw pain) were noted in 18.0%. Two additional patients not experiencing cranial symptoms exhibited large vessel involvement with confirmed carotid thickening on non-invasive angiography; one of these had a positive temporal artery biopsy. Conclusion VEXAS syndrome manifests as a variable vessel vasculitis in a quarter of patients, with cutaneous small and medium vessel involvement being particularly common. Some patients may have positive ANCA serologies or even renal vasculitis leading to misdiagnosis. Cranial symptoms are common and may mimic GCA, though documented large vessel inflammation is rare.
The ABCs of Subarachnoid Hemorrhage Blood Volume Measurement: A Simplified Quantitative Method Predicts Outcomes and Delayed Cerebral Ischemia
Föttinger, Fabian, Sharma, Rohan , Salman, Saif , Weston, Alexander D. , Erickson, Bradley J. , Huynh, Thien , Tawk, Rabih G. , Freeman, William D. , Salman, Saif D, Tawk, Rabih G , Freeman, William D , Erickson, Bradley J , Huynh, Thien , Weston, Alexander D

Mayo Clinic

Journal of the American Heart Association | October 11, 2024 | Volume: 13 | Issue: 20 | Pages: No page available

10.1161/jaha.123.032195 | PMID 39392139 Get It

Background We developed a simplified ABC/2‐derived method to estimate total subarachnoid hemorrhage volume (SAHV) on noncontrast computed tomography in patients with aneurysmal SAH and compared the clinical and radiographic outcomes. Methods and Results In this retrospective observational cohort study, we analyzed 277 patients with SAH admitted to our Comprehensive Stroke Center between 2012 and 2022. We derived a mathematical model (model 1) by measuring SAH basal cisternal blood volume using an ABC/2‐derived ellipsoid formula (A=width/thickness, B=length, C=vertical extension) on head noncontrast computed tomography in 5 major SAH cisternal compartments. We compared model 1 against a manual segmentation method (model 2) on noncontrast computed tomography. Data were analyzed using logistic regression analysis, t test, receiver operator characteristic curves, and area under the curve analysis. There was no significant difference in cisternal SAHV analysis between the 2 models ( P =0.14). Mean SAHV by the simplified method was 7.0 mL (95% CI, 5.89–8.09) for good outcome and 16.6 mL (95% CI, 13.49–19.77) for poor outcome. Patients with delayed cerebral ischemia had higher SAHV, with a cutoff value of 10 mL. Conclusions Our simplified ABC/2‐derived method to estimate SAHV is comparable to manual segmentation and can be performed in low‐resource settings. Higher total SAHV was associated with worse outcomes and higher risk of delayed cerebral ischemia. A potential dose–response relationship was observed, with SAHV >10 mL predicting worse outcomes and higher risk of DCI.
A Multicenter Analysis of 3 Decades of Hip Arthroscopy: Evolving Techniques and Growing Patient Volumes From 1988 to 2022
Conyer, Ryan T. , Cleary, Emmett J., Wang, Allen S. , Boos, Alex M., Crowe, Matthew M. , Krych, Aaron J. , Levy, Bruce A. , Hevesi, Mario , Boos, Alexander M. , Economopoulos, Kostas J. , Krych, Aaron J , Hevesi, Mario , Wang, Allen , Boos, Alexander

Mayo Clinic

Orthopaedic Journal of Sports Medicine | October 10, 2024 | Volume: 12 | Issue: 10 | Pages: No page available

10.1177/23259671241277793 | PMID 39399769 Get It

Background: The number of hip arthroscopies performed in the United States has grown significantly over the past several decades, with evolving indications and emerging techniques. Purposes: To (1) examine the evolution of hip arthroscopy at 3 tertiary referral centers between 1988 and 2022 and (2) quantify trends in patient demographics and procedures performed. Study Design: Case series; Level of evidence, 4. Methods: A retrospective analysis was performed of all patients undergoing hip arthroscopy at 3 academic centers between 1988 and 2022. Demographic data were collected using standardized forms and operative notes, and intraoperative images were manually reviewed for each patient to determine the specific procedures performed at the time of the hip arthroscopy. Surgical procedures were plotted over time to evaluate trends. Patients were divided into 3 time periods for comparison: early hip arthroscopy from 1988 to 2008, 2009 (the time of the first labral repair in our cohort) to 2015, and 2016 to 2022. Results: A total of 3000 patients (age, 35.7 ± 13.8 years; age range, 10-89 years; female sex, 2109 (70.3%); body mass index, 27.4 ± 6.3 kg/m 2 ) underwent arthroscopic hip procedures between 1988 and 2022. The mean number of cases increased from a mean of 3.2 per year in 1988-2008 to 285.9 per year in 2016-2022 ( P < .001). Labral treatment at the time of primary hip arthroscopy evolved from 100% debridement and 0% repair in 1988-2008 to 5.0% debridement, 94.0% repair, and 1.0% labral reconstruction in 2016-2022 ( P < .001). Cam resection increased from 4.1% in 1988-2008 to 86.9% in 2016-2022 ( P < .001). By 2022, 45 out of 325 cases (13.8%) were revisions. The rate of capsular repair at the time of primary hip arthroscopy increased from 0.0% in 1988-2008 up to 81.0% in 2016-2022. Conclusion: There has been a significant growth of hip arthroscopy volumes as well as a significant transition from use as a tool for diagnosis and labral debridement to procedures restoring native anatomy including labral repair, cam resection, capsular repair, periacetabular osteotomy, and gluteal repair.
Paper 21: Anatomic Medial Ulnar Collateral Ligament Reconstruction with Internal Brace Augmentation in Throwing Athletes
Jurgensmeier, Kevin , Boos, Alex, Hintz, Christian, Dines, Joshua, Jurgensmeier, Kevin , Camp, Christopher L. , Boos, Alexander M. , Hintz, Christian

Mayo Clinic

Orthopaedic Journal of Sports Medicine | October 9, 2024 | Volume: 12 | Issue: 7_suppl2 | Pages: No page available

10.1177/2325967124s00034 Get It

Objectives: Injury to the Medial Ulnar Collateral Ligament (MUCL) is a common setback experienced by many throwing athletes often requiring reconstruction with 12-18 months of rehabilitation. Current reconstructive techniques fail to anatomically restore the MUCL which may contribute to the prolonged course of rehabilitation. In recent years, we described an anatomic MUCL reconstruction with internal brace augmentation which demonstrated improved biomechanical strength when compared to the docking technique in cadaveric specimens. The purpose of this study was to evaluate the postoperative course of both amateur and professional throwing athletes that underwent anatomic MUCL reconstruction with internal brace augmentation. We hypothesized that throwers would return to the same level of play and that return to play (RTP) would be a shorter duration compared to current reported outcomes. Methods: In this surgical technique, the native MUCL is formally repaired. The graft and a suture tape are folded over a suspensory loop and secured in a socket of the medial epicondyle of the humerus to maximize tendon to bone contact. On the ulnar side, the graft and internal brace are secured proximally by two suture anchors on either side of the sublime tubercle and further secured across the sublime tubercle ridge distally to re-create the anatomic triangular insertion of the native ligament. All surgeries were performed by a single surgeon. Patient reported outcomes in addition to date of RTP, level of play, and functional outcomes were retrospectively gathered. All patients initially followed an Accelerated Rehabilitation Protocol and were converted to a Standard Paced protocol if setbacks were encountered. Results: A total of 26 baseball players underwent primary (n=23) or revision (n=3) MUCL reconstruction with the Anatomic Technique. Of these, 15 were professional and 11 were amateur athletes. 92% of throwers returned to play at a mean of 9.9 months following reconstruction. 89% were able to advance through the accelerated postoperative protocol without issues and 85% returned to the same role and level of play. Post injury KJOC scores improved from 41 to 86.9 and SANE scores improved from 32.5 to 95.5. No significant difference was identified in pre-injury versus post-reconstruction throwing velocity, ball spin rate, or horizontal/vertical ball movement. Conclusions: Anatomic reconstruction of the MUCL with internal bracing is a viable option for MUCL injuries. Advantages include increased tendon-bone contact of the reconstruction, multiple fixation points, and anatomic restoration of the MUCL. This technique allowed an expedited return to sport for these baseball athletes.
7376 Efficacy and Safety of CAM2029 in Patients With Controlled or Inadequately Controlled Acromegaly on Standard-of-Care Treatment: Interim Data for the “New to CAM2029” Patient Subgroup in a Phase 3 Study (ACROINNOVA 2)
Yaylalı, Güzin Fidan , Doknić, Mirjana , Dreval, Alexander , Gilis‐Januszewska, Aleksandra , Harrie, Maria, Svedberg, Anna , Pedroncelli, Alberto M, Tiberg, Fredrik , Ferone, Diego , Spencer-Segal, Joanna L. , Isaeva, E, Gezer, Emre , Bancos, Irina , Katznelson, Laurence , Svedberg, A

Mayo Clinic

Journal of the Endocrine Society | October 5, 2024 | Volume: 8 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvae163.1200 Get It

Abstract Disclosure: D. Ferone: Consulting Fee; Self; Camurus AB, Ipsen, Novartis-AAA, Recordati. Grant Recipient; Self; Camurus AB, Ipsen, Novartis-AAA, Recordati. Research Investigator; Self; Camurus AB. J.L. Spencer-Segal: Advisory Board Member; Self; Camurus AB. Research Investigator; Self; Camurus AB. G. Fidan Yaylali: None. M. Doknic: Speaker; Self; Pfizer, Inc., Novo Nordisk, Merck, Sandoz. E. Isaeva: None. A. Dreval: None. A. Gilis-Januszewska: None. E. Gezer: None. I. Bancos: Advisory Board Member; Self; Diurnal, Spruce, Neurocrine, Adrenas, Sparrow, Corcept, HRA Pharmaceuticals, Recordati, Xeris, AstraZeneca, Novo Nordisk. Grant Recipient; Self; Recordati, HRA Pharmaceuticals. L. Katznelson: Advisory Board Member; Self; Camurus AB, Recordati. M. Harrie: Employee; Self; Camurus AB. Stock Owner; Self; Camurus AB. A. Svedberg: Employee; Self; Camurus AB. Stock Owner; Self; Camurus AB. A.M. Pedroncelli: Employee; Self; Camurus AB. Stock Owner; Self; Camurus AB. F. Tiberg: Employee; Self; Camurus AB. Stock Owner; Self; Camurus AB. Background: Acromegaly is a rare, serious disorder characterized by overproduction of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). There is a need for new, convenient therapies that provide effective disease control. CAM2029 is a novel subcutaneous octreotide depot designed for convenient once-monthly self-administration (ready-to-use syringe or injection pen). In a 24-week, Phase 3 trial (ACROINNOVA 1), CAM2029 was superior to placebo at attaining IGF-1 response (≤upper limit of normal [ULN] at week 22/24: 72.2% vs 37.5%; P=0.0018) in patients with acromegaly previously controlled under standard of care (SoC; octreotide long-acting repeatable [LAR]/lanreotide Autogel). Here, we report interim data from another Phase 3 trial of CAM2029 (ACROINNOVA 2; NCT04125836), focusing on the “New to CAM2029” subgroup of patients whose acromegaly was either controlled or uncontrolled under SoC. Methods: This 52-week, Phase 3, open-label trial (with a 52-week extension) enrolled patients who had received CAM2029 or placebo in ACROINNOVA 1 (reported separately) and “New to CAM2029” patients who were adequately or inadequately controlled (IGF-1 ≤2x ULN) on a stable dose of octreotide LAR/lanreotide Autogel for ≥3 months (data reported here). In the main part of the trial, new patients received once-monthly CAM2029 20 mg for up to 52 weeks. The primary endpoint was adverse events (AEs). Secondary endpoints included (i) the proportion of patients with IGF-1 ≤1x ULN (weeks 50/52 mean), (ii) the change from baseline in IGF-1, and (iii) the combined IGF-1 and GH response. Baseline values reflected SoC treatment. Data cutoff: May 23, 2023. Results: Eighty-one new patients were enrolled (mean age 51.8 years; 59.3% female). No new or unexpected safety signals were observed. The most common treatment-emergent AEs were injection site erythema (n=22) or swelling (n=13), and headache (n=12). AEs were mostly mild (grade 1/2); there were no serious or Grade 3 treatment-related AEs attributed to CAM2029. IGF-I response increased from 14.8% at baseline SoC (12/81) to 33.3% (20/60 patients with available data) at weeks 50/52. The estimated increase in IGF-1 response (linear probability model) from baseline at week 52 was 21.9% (95% CI: 9.6, 34.1). Biochemical control for both IGF-1 and GH improved over time: 30.0% of patients (18/60) had a combined IGF-1 and GH response at the end of the main part of trial, vs 11.7% (7/60) at baseline. Conclusion: CAM2029 was well tolerated with a safety profile consistent with that of SoC. Biochemical control rates improved from SoC baseline over 52 weeks of CAM2029 treatment in the “New to CAM2029” patients. These findings reinforce the efficacy and safety of CAM2029 in patients with acromegaly, including patients with uncontrolled disease with current SoC treatment (octreotide LAR/lanreotide Autogel). Presentation: 6/1/2024